On the contrary, N-Glc MEP 24 displays an interesting ability to identify in SP-ELISA both IgG and IgM antibodies in a large number of MS patients’ sera (81) compared to controls (30), with a sensitivity of 35% (95% CI: 14.21–61.67) and a specificity of 92.31 (95% CI: 63.97–99.81). The gene discussed is CD40LG; the disease is myeloid sarcoma.